ASND Relative Valuation
ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASND is overvalued; if below, it's undervalued.
Historical Valuation
Ascendis Pharma A/S (ASND) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.26. The fair price of Ascendis Pharma A/S (ASND) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：208.58
Fair
98.55
PE
1Y
3Y
5Y
Trailing
Forward
89.72
EV/EBITDA
Ascendis Pharma A/S. (ASND) has a current EV/EBITDA of 89.72. The 5-year average EV/EBITDA is -7.76. The thresholds are as follows: Strongly Undervalued below -117.65, Undervalued between -117.65 and -62.70, Fairly Valued between 47.19 and -62.70, Overvalued between 47.19 and 102.13, and Strongly Overvalued above 102.13. The current Forward EV/EBITDA of 89.72 falls within the Overvalued range.
52.39
EV/EBIT
Ascendis Pharma A/S. (ASND) has a current EV/EBIT of 52.39. The 5-year average EV/EBIT is -11.95. The thresholds are as follows: Strongly Undervalued below -76.34, Undervalued between -76.34 and -44.15, Fairly Valued between 20.25 and -44.15, Overvalued between 20.25 and 52.44, and Strongly Overvalued above 52.44. The current Forward EV/EBIT of 52.39 falls within the Overvalued range.
8.81
PS
Ascendis Pharma A/S. (ASND) has a current PS of 8.81. The 5-year average PS is 122.17. The thresholds are as follows: Strongly Undervalued below -328.93, Undervalued between -328.93 and -103.38, Fairly Valued between 347.72 and -103.38, Overvalued between 347.72 and 573.28, and Strongly Overvalued above 573.28. The current Forward PS of 8.81 falls within the Historic Trend Line -Fairly Valued range.
35.28
P/OCF
Ascendis Pharma A/S. (ASND) has a current P/OCF of 35.28. The 5-year average P/OCF is 9.52. The thresholds are as follows: Strongly Undervalued below -1587.52, Undervalued between -1587.52 and -789.00, Fairly Valued between 808.05 and -789.00, Overvalued between 808.05 and 1606.57, and Strongly Overvalued above 1606.57. The current Forward P/OCF of 35.28 falls within the Historic Trend Line -Fairly Valued range.
34.63
P/FCF
Ascendis Pharma A/S. (ASND) has a current P/FCF of 34.63. The 5-year average P/FCF is -17.49. The thresholds are as follows: Strongly Undervalued below -58.94, Undervalued between -58.94 and -38.21, Fairly Valued between 3.23 and -38.21, Overvalued between 3.23 and 23.95, and Strongly Overvalued above 23.95. The current Forward P/FCF of 34.63 falls within the Strongly Overvalued range.
Ascendis Pharma A/S (ASND) has a current Price-to-Book (P/B) ratio of -62.88. Compared to its 3-year average P/B ratio of -27.18 , the current P/B ratio is approximately 131.33% higher. Relative to its 5-year average P/B ratio of -12.90, the current P/B ratio is about 387.53% higher. Ascendis Pharma A/S (ASND) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.22%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.46% , the current FCF yield is about -100.00% lower.
-62.88
P/B
Median3y
-27.18
Median5y
-12.90
-1.07
FCF Yield
Median3y
-6.22
Median5y
-6.46
Competitors Valuation Multiple
The average P/S ratio for ASND's competitors is , providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 269.40%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ASND increased by 51.51% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 57.83M to 213.63M.
The secondary factor is the Margin Expansion, contributed -83.35%to the performance.
Overall, the performance of ASND in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Ascendis Pharma A/S (ASND) currently overvalued or undervalued?
What is Ascendis Pharma A/S (ASND) fair value?
How does ASND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ascendis Pharma A/S (ASND) as of Dec 05 2025?
What is the current FCF Yield for Ascendis Pharma A/S (ASND) as of Dec 05 2025?
What is the current Forward P/E ratio for Ascendis Pharma A/S (ASND) as of Dec 05 2025?